Wearable Brain Stimulation Device Gains FDA Fast Track for Addiction
The FDA has granted Breakthrough Device designation to NET Recovery's transcranial alternating current stimulation wearable, which is designed to reduce cocaine and methamphetamine use. The designation is intended to accelerate development of a treatment for a condition with few approved options.
The U.S. Food and Drug Administration has awarded Breakthrough Device designation to a wearable system developed by NET Recovery. This regulatory status is reserved for technologies that show potential to address serious conditions more effectively than existing options, and it is meant to shorten the pathway toward market approval.
The device employs transcranial alternating current stimulation, a non-invasive technique that delivers low-level electrical signals to the brain. Its intended purpose is to help reduce dependence on cocaine and methamphetamine, substances for which approved treatment tools remain scarce. The designation highlights an ongoing shift toward neuromodulation as a possible avenue for addiction care, though clinical testing and regulatory review still lie ahead.
This designation could signal growing acceptance of brain-stimulation technologies as practical tools for addiction treatment. If the device proves effective, it may offer a new option for clinicians and patients facing stimulant use disorders, a population with limited pharmacological choices. It could also encourage further investment in wearable neurotherapeutics, potentially reshaping how addiction care is delivered outside clinical settings. However, real-world impact will depend on trial outcomes, accessibility, and whether insurers and treatment programs adopt the technology.